The QualityStocks Daily Monday, June 30th, 2025

Today's Top 3 Investment Newsletters

Premium Stock Alerts(BMNR) $33.9000 +694.84%

QualityStocks(ARTL) $13.2700 +95.43%

MarketClub Analysis(IPDN) $3.3800 +93.14%

The QualityStocks Daily Stock List

Artelo Biosciences (ARTL)

QualityStocks, MarketBeat, MarketClub Analysis, StocksEarning, MicroCap Press, TopPennyStockMovers, The Stock Dork, The Online Investor, Streetwise Reports, StockWireNews, Schaeffer's and Fierce Analyst reported earlier on Artelo Biosciences (ARTL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Artelo Biosciences Inc. (NASDAQ: ARTL) is a clinical stage biopharmaceutical firm that is en-gaged in the development and commercialization of therapies that modulate the endocannabinoid system.

The firm has its headquarters in La Jolla, California and was incorporated in 2011, on May 2nd by James Manley. Prior to its name change in April 2017, the firm was known as Reactive Medical Inc. It operates as part of the healthcare sector, under the biotech and pharma sub-industry.

The company is party to a research collaboration with Trinity College Dublin which entails the in-vestigation of ART27.13, a formulation indicated for the treatment of cancer cachexia. It offers product candidates that treat inflammatory, cardiovascular and neurodegenerative disorders; as well as pain, tissue injury, nausea caused by chemotherapy and metabolic/obesity syndrome. The com-pany’s products can significantly enhance patient care in major markets.

The enterprise’s product pipeline is made of a fatty acid binding protein 5 inhibitor indicated for the treatment of post-traumatic stress disorder, breast and prostate cancer treatment dubbed ART26.12; a synthetic cannabidiol cocrystal developed for treating post-traumatic stress disorder and inflam-matory bowel disease termed ART12.11 and a synthetic G protein-coupled receptor agonist dubbed ART27.13, which is currently undergoing a phase 1 clinical trial evaluating its effective-ness in treating anorexia linked to cancer.

Artelo Biosciences (ARTL), closed Monday's trading session at $13.27, up 95.4345%, on 27,022,818 volume. The average volume for the last 3 months is 22,610 and the stock's 52-week low/high is $4.9176/$25.58.

Professional Diversity Network (IPDN)

RedChip, QualityStocks, StockMarketWatch, TraderPower, StockOodles, ResearchOTC, PennyStockLocks.com, StockRockandRoll, Penny Pick Finders, PennyStockProphet, Monster Stocks, MarketBeat, Premium Stock Alerts, InvestorPlace, Investing Futures, Buzz Stocks, Marketbeat.com, PennyStocks24, BUYINS.NET, PoliticsAndMyPortfolio, SecretStockPromo, Stock Commander, Stock Guru, StockOnion, The Street and Planet Penny Stocks reported earlier on Professional Diversity Network (IPDN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Professional Diversity Network Inc. (NASDAQ: IPDN) (FRA: 5MQ) is a holding firm that oper-ates as an online professional networking community with career resources.

The firm has its headquarters in Chicago, Illinois and was incorporated in 2003, on October 3rd by Rudy Martinez. It serves consumers in the United States.

The company operates through the Corporate overhead, National Association of Professional Women and the Professional Diversity Network segments. The professional women segment refers to a women-only professional networking organization while the diversity network segment com-prises of online professional networking communities that have resources which are tailored to the needs of different cultural groups.

The enterprise provides recruitment services, including e-newsletter marketing, hiring campaign marketing and advertising, corporate memberships, talent recruitment communities, recruitment media, multiple and single job postings and outreach and research services to different employers and cultural groups. It also offers consumer marketing and consumer advertising solutions via job postings and advertising on its minority-focused websites, which include AMightyRiver.com, which serves African-American professionals and iHispano.com, which caters to Hispanic-American professionals. The websites facilitate professional networking within social and ethnic communities. The enterprise also operates sites which serve other societal subsets, like veteran mili-tary personnel as well as those who’ve enlisted to join the army, lesbians and gays, Asian-Americans and women.

Professional Diversity Network (IPDN), closed Monday's trading session at $3.38, up 93.1429%, on 55,197,078 volume. The average volume for the last 3 months is 9,787,516 and the stock's 52-week low/high is $0.9682/$11.2.

Exicure, Inc. (XCUR)

StockEarnings, QualityStocks, PCG Advisory, MarketBeat, StocksEarning, Premium Stock Alerts, StockMarketWatch, Timothy Sykes, The Online Investor, MarketClub Analysis, InvestorsUnderground, InsiderTrades, FreeRealTime and 360 Wall Street reported earlier on Exicure, Inc. (XCUR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Exicure, Inc. is the pioneer in gene regulatory and immunotherapeutic drugs employing proprietary Spherical Nucleic Acid (SNA™) technology. A clinical-stage biotechnology company, it is developing ther-apeutics for neurology, immuno-oncology, inflammatory diseases, and also other genetic disorders based on its proprietary SNA technology. SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. Established in 2011, Exicure has its corporate headquarters in Chicago, Illinois. The Company’s shares trade on the Nasdaq Global Select Market.

Exicure’s belief is that its proprietary SNA architecture has distinct chemical and biological properties, which may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not normally addressed with other nucleic acid therapeutics. The Company is in pre-clinical development of XCUR-FXN, an SNA–based therapeutic candidate, for the treatment of Frie-dreich’s ataxia (FA).

The design of Exicure's proprietary SNA™ architecture is to unlock the potential of therapeutic oligonu-cleotides in a broad array of cells and tissues. SNA constructs overcome one of the most difficult obsta-cles to nucleic acid therapeutics. This is safe and effective delivery into cells and tissues. The Company’s Intellectual Property (IP) portfolio includes greater than 135 pending patent applications and more than 60 allowed or issued patents.

Exicure’s pipeline also includes Cavrotolimod (AST-008). Cavrotolimod (AST-008) is a toll-like receptor 9 agonist. The design of it is to activate the innate immune system and induce a potent anti-cancer im-mune response, particularly in combination with checkpoint inhibitors.

Exicure, Inc. (XCUR), closed Monday's trading session at $7.04, up 19.5246%, on 4,261,584 volume. The average volume for the last 3 months is 6,556,795 and the stock's 52-week low/high is $1.44/$36.

Ginkgo Bioworks (DNA)

MarketClub Analysis, Schaeffer's, InvestorPlace, Kiplinger Today, The Street, TradersPro, INO Market Report, Premium Stock Alerts, MarketBeat, QualityStocks, InsiderTrades, Streetwise Reports, Trades Of The Day, Shah's Insights & Indictments, Alternative Energy, SmallCapFinancialWire, StocksEarning, Investor Ideas, Investor Guide, FreeRealTime, Earnings360, CRWEFinance and Money Morning reported earlier on Ginkgo Bioworks (DNA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The firm has its headquarters in Boston, Massachusetts and was incorporated in 2008. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers across the globe.

The company’s platform is market agnostic and enables biotech applications across diverse markets from industrial chemicals and pharmaceuticals to food and agriculture. It is party to a partnership with Selecta Biosciences Inc., which involves developing ImmTOR technology platform.

The enterprise operates through the Biosecurity and Foundry segments. The Biosecuri-ty segment comprises of coronavirus testing products and services which are mainly provided to public health authorities. On the other hand, the Foundry segment com-prises of research and development services performed under license and collaboration agreements associated with the firm’s cell programming platform. The programming platform consists of biology lab facilities and the foundry, which are paired with a col-lection of biological parts and database of biological data used to program cells known as Codebase. The enterprise serves various end markets, including pharmaceuticals, consumer products, food, agriculture and specialty chemicals.

Ginkgo Bioworks (DNA), closed Monday's trading session at $11.25, up 18.9218%, on 2,797,222 volume. The average volume for the last 3 months is 659,125 and the stock's 52-week low/high is $5/$16.85.

CDT Environmental Technology Investment (CDTG)

We reported earlier on CDT Environmental Technology Investment (CDTG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) is a company focused on designing, developing, manufacturing, selling, installing, operating, and maintaining sewage treatment systems, focusing on innovative solutions for sustainable environmental prac-tices.

The firm has its headquarters in Shenzhen, China and was incorporated in 2016, on November 28th. It operates as part of the waste management industry, under the industrials sector. The firm mainly serves consumers in the People’s Republic of China.

CDTG Environmental Technology Investment operates through the Sewage Treatment Systems and the Sewage Treatment Services segments. The Sewage Treatment Systems segment focuses on the sale of complete sewage treatment systems, constructs rural sewage treatment plants, in-stalls the systems, and offers on-going operation and maintenance services for such systems and plants in China for municipalities and enterprise clients. On the other hand, the Sewage Treat-ment Services segment provides on-site, or in-situ, septic tank treatment services in the urban and rural areas of China for municipalities and residential and business property management compa-nies. It has developed both mobile and fixed systems to meet the various needs of its clients. As of December 31, 2023, the enterprise had 2 invention patents, 38 utility model patents, 3 trade-marks, and 2 software copyrights. It has completed over 150 plants across the country.

The company is continually working to upgrade its quick separation technology and septic tank treatment systems through independent research and development and partnerships with third-party institutions and remains focused on long-term investment opportunities in water conserva-tion and environmental regulation. This may in turn open it up to new opportunities for growth and expansion.

CDT Environmental Technology Investment (CDTG), closed Monday's trading session at $0.7, off by 5.4054%, on 50,925 volume. The average volume for the last 3 months is 95,860 and the stock's 52-week low/high is $0.52/$4.64.

Aston Bay Holdings Ltd. (ATBHF)

QualityStocks, SmallCapRelations, SeriousTraders, MissionIR, MiningNewsWire, InvestorBrandNetwork, ESGWireNews, Stocks to Buy Now, Tip.us, StocksToBuyNow, SmallCapSociety, Rocks & Stocks, NetworkNewsWire, rocksandstocks and ESGWireNews Editor reported earlier on Aston Bay Holdings Ltd. (ATBHF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As the biggest producer of cobalt on the globe, any action that the Democratic Republic of Congo takes is, on paper, expected to have a significant effect on the market for this metal. So, why didn’t Congo’s expiring moratorium on cobalt exports have the desired effect of shoring up cobalt prices on the world stage to the extent that the ban has been extended for another three months?

First, cobalt from the DRC takes at least three months to be shipped to the People’s Republic of China (PRC) where it is refined prior to its sale on the world market. This lag means that the previous export ban that the DRC imposed couldn’t yield the desired effect within the time in which it was in force because previous shipments were making landfall in China. This lagging effect means that for the DRC to see results from its export curbs, the duration of the curb has to be extended so that shipments landing in China dwindle or even stop altogether.

The other pitfall standing in the way of the export ban attaining the desired effect is that cobalt isn’t mined as a standalone mineral. Rather, it is a byproduct of the mining of copper. In effect, copper miners get cobalt as a free extra product that they can sell. What this means for the DRC is that while it can temporarily ban the export of the metal, stockpiles will keep accumulating domestically and these will, sooner or later, have to be released onto the global market.

To compound matters, copper is currently hot on the world market so all companies producing copper around the globe also have some cobalt available for sale. The incentive to mine more copper means supplies of cobalt will also remain high.

The kicker is that cobalt was in high demand for EV battery manufacturing, but many firms have since switched to other battery chemistries that require minimal or no cobalt in their products. So, while there are nearly endless supplies of cobalt on the market, the demand for the metal is declining or isn’t growing in tandem with the growth in cobalt supply around the world.

What option does Congo have to address the free-falling cobalt prices? Learn from Indonesia. Indonesia enacted laws that required nickel and copper to be processed domestically rather than being exported as an ore. By doing this, the country has been able to earn more revenue from these metals while establishing downstream operations that create jobs, earn local authorities tax income and elevate the country’s role in the supply chains of these metals.

Congo could borrow a leaf from the lead provided by Indonesia so that it can earn more from processed cobalt rather than trying to influence the market for the metal’s ore. Is this a switch that the country’s leadership can pull off? It depends on how their policymakers assess the current problem and the choices they make as lasting solutions to the problem.

For gold and copper exploration firms like Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), the current headwinds in the market for cobalt present learning moments that they can factor into their strategic planning processes so that their projections aren’t thrown out of whack in the long term.

Aston Bay Holdings Ltd. (ATBHF), closed Monday's trading session at $0.0487, off by 2.0121%, on 4,400 volume. The average volume for the last 3 months is 12,351,720 and the stock's 52-week low/high is $0.03095/$0.107.

Tilray Brands Inc. (TLRY)

QualityStocks, Schaeffer's, InvestorPlace, StockEarnings, StocksEarning, The Street, CannabisNewsWire, MarketClub Analysis, MarketBeat, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, Zacks, BUYINS.NET, Investopedia, CFN Media Group, Premium Stock Alerts, Early Bird, CNBC Breaking News, INO Market Report, The Street Report, Daily Profit, StreetAuthority Daily, FreeRealTime, Earnings360, Top Pros' Top Picks, Trading For Keeps, Trading Concepts, Prism MarketView, The Rich Investor, Tip.us, InvestmentHouse, Inside Trading, Daily Wealth, AllPennyStocks, InsiderTrades, Investment House, Eagle Financial Publications, Outsider Club, wyatt research newsletter, Wealth Daily, VectorVest, TradersPledge, TipRanks, TheTradingReport, The Night Owl, StrategicTechInvestor, MarketClub, Rick Saddler, Investors Alley, Money Morning, 360 Wall Street, Marketbeat.com, Louis Navellier, Jim Cramer, Jason Bond, InvestorsUnderground, InvestorsObserver Team and Stock Up Featured reported earlier on Tilray Brands Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

State lawmakers in Ohio are likely to head into their summer recess without passing any revisions to the current cannabis regulations. 

Senate Bill 56 (SB 56), which proposes revisions to Ohio’s recreational cannabis laws, has been stalled in the House Judiciary Committee for two consecutive weeks. The committee canceled a scheduled meeting this week, which only listed SB 56 on its agenda, and previously removed the bill from the agenda altogether. 

“We’re hitting pause for the summer,” Representative Brian Stewart said. “We might come back to it later and try again.” 

The Senate approved the bill in February, but it needs approval from the House before it can become law. House Speaker Matt Huffman explained that while the Senate is eager to move forward, the House doesn’t want to compromise its legislative goals just to pass the legislation quickly. 

Currently, legislators are finalizing the state’s two-year budget, which must be finalized by July 1. Once that’s done, the legislature will begin its summer recess. 

SB 56 proposes lowering the THC cap in recreational cannabis extracts from 90% to 70%, capping dispensaries at 400 locations, and restricting smoking in most public areas. It keeps the existing home-grow rules at six plants per adult and 12 per household. The bill, introduced in January by Senator Steve Huffman, originally aimed to cut the home-grow limit in half. 

Voters approved recreational cannabis in 2023 through a citizen-led initiative, which passed with 57% support. Retail sales began in August 2024. Since the law originated from a citizen petition and not an amendment, lawmakers have the authority to amend it. 

House Democrats argue that the bill undermines the will of the voters. Representative Dani Isaacsohn said, “Ohioans chose to legalize recreational cannabis. They understood the measure and supported it.” 

Among the most debated provisions are new restrictions on hemp products. Currently, the bill states that only licensed dispensaries can sell the products, which would need to meet strict advertising, packaging, and labeling rules. However, stores like groceries, restaurants, and convenience shops can still sell hemp-infused beverages. Oversight would fall to the state’s Commerce Department. 

Isaacsohn agrees that hemp rules are necessary but wants them handled separately. Meanwhile, Representative D.J. Swearingen, who had planned to present changes to the hemp portion of the bill, was unable to do so due to the canceled committee meeting. 

He worked with the American Republic Policy on proposals that would let existing hemp businesses keep their doors open. Dakota Sawyer from the group said the goal was to prevent monopolies and allow small businesses to continue operating outside the dispensary model. 

Governor DeWine and some lawmakers have voiced concerns about minors accessing hemp products. But Sawyer pointed out that the average Ohio hemp consumer is about 40 years old. He accused some legislators of exaggerating risks to justify restrictions. 

Sawyer suggested splitting marijuana and hemp legislation into two separate bills, arguing that combining them only complicates progress. 

The discussions in Ohio are likely to attract interest from far and wide, including from firms like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY), given how high the stakes are, including the regulation of hemp products within state borders. 

Tilray Brands Inc. (TLRY), closed Monday's trading session at $0.4144, up 3.419%, on 17,808,172 volume. The average volume for the last 3 months is 212,143,639 and the stock's 52-week low/high is $0.3507/$2.15.

Tonix Pharmaceuticals (TNXP)

QualityStocks, InvestorBrandNetwork, BioMedWire, SeriousTraders, SmallCapRelations, Stocks to Buy Now, NetworkNewsWire, MissionIR, SmallCapSociety, StocksToBuyNow, Tip.Us, TinyGems, StockMarketWatch, MarketClub Analysis, Premium Stock Alerts, BUYINS.NET, TraderPower, MarketBeat, InvestorPlace, The Online Investor, PennyStockLocks, StockRockandRoll, 360 Wall Street, StreetInsider, Penny Stock 101, Barchart, RedChip, Marketbeat.com, HotOTC, INO.com Market Report, OTCtipReporter, Buzz Stocks, Penny Pick Finders, Daily Trade Alert, StockOnion, PennyStockProphet, Trades Of The Day, TopPennyStockMovers, Streetwise Reports, Profitable Trader Authority, Street Insider, Wealth Insider Alert, The Street, Early Bird, Fanchon Sweet, FeedBlitz, StockReport, Investing Futures, plrinvest, Small Cap Firm, Penny Stock 103, InvestorsUnderground, Jason Bond, Schaeffer's, Promotion Stock Secrets, MarketWatch, Prism MarketView, Weekly Wizards, neupretpurireae6, Penny Stock 109 and Investment House reported earlier on Tonix Pharmaceuticals (TNXP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biotech company, announced its inclusion in the Russell 3000® and Russell 2000® Indexes following the 2025 Russell indexes reconstitution effective June 30. The addition reflects Tonix’s market cap growth and comes as the company prepares for potential FDA approval and launch of TNX-102 SL for fibromyalgia. CEO Seth Lederman noted the milestone will boost visibility as Tonix progresses toward commercialization. Russell indexes are widely used benchmarks, with $10.6 trillion in assets tied to their performance.

To view the full press release, visit https://ibn.fm/KCfwJ

About Tonix Pharmaceuticals Holding Corp.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com .

Tonix Pharmaceuticals (TNXP), closed Monday's trading session at $35.98, up 3.1241%, on 716,155 volume. The average volume for the last 3 months is 10,491,448 and the stock's 52-week low/high is $6.76/$130.

Quantum BioPharma (QNTM)

QualityStocks, SmallCapRelations, BioMedWire, InvestorBrandNetwork, MissionIR, SeriousTraders, StocksToBuyNow, Tip.Us, NetworkNewsWire, TinyGems, SmallCapSociety, Stocks to Buy Now, TechMediaWire, Tiny Gems, StockWireNews, Fierce Analyst, 360 Wall Street, Premium Stock Alerts and Timothy Sykes reported earlier on Quantum BioPharma (QNTM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quantum BioPharma (NASDAQ: QNTM) , a biopharmaceutical company focused on innovative biotech assets, announced a non-brokered private placement of class A multiple voting shares (MVS) at $50 per share for gross proceeds of up to $600. The offering is expected to be fully subscribed by existing MVS holders, including entities linked to CEO Zeeshan Saeed and director Anthony Durkacz. As a related-party transaction under MI 61-101, the company relied on exemptions due to the transaction’s limited size relative to market capitalization. Proceeds will support general working capital. All issued securities will carry a four-month-plus-one-day hold under Canadian securities laws.

To view the full press release, visit https://ibn.fm/9A9Lc

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD(TM) and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com . The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma (QNTM), closed Monday's trading session at $20.25, off by 6.768%, on 265,639 volume. The average volume for the last 3 months is 175,562 and the stock's 52-week low/high is $2.7/$38.25.

Trillion Energy (TRLEF)

QualityStocks, SmallCapRelations, SeriousTraders, MissionIR, MiningNewsWire, InvestorBrandNetwork, Stocks to Buy Now, Tip.us, StocksToBuyNow, SmallCapSociety, Rocks & Stocks and NetworkNewsWire reported earlier on Trillion Energy (TRLEF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trillion Energy (CSE: TCF) (OTCQB: TRLEF) will issue 7,725,908 common shares at $0.05 per share to settle $386,295.42 in debt owed to directors, officers, and consultants. Of this, 3.9 million shares are being issued to management in a related-party transaction under MI 61-101. The company relied on exemptions from formal valuation and minority approval requirements, as the insider portion represents less than 25% of its market capitalization. All shares will be subject to a four-month-plus-one-day hold under Canadian securities law.

To view the full article, visit https://ibn.fm/Vttps

About Trillion Energy International Inc.

Trillion Energy is focused on oil and natural gas production for Europe and Türkiye with natural gas assets in Türkiye. The company holds a 49% interest in the SASB natural gas field, a Black Sea natural gas development and 19.6% (except three wells with 9.8%) interest in the Cendere oil field. The company also is pursuing oil exploration in S.E. Turkiye and beyond. More information may be found on www.sedar.com and the company’s website .

Trillion Energy (TRLEF), closed Monday's trading session at $0.0285, off by 9.2357%, on 505,001 volume. The average volume for the last 3 months is 322,930 and the stock's 52-week low/high is $0.017/$0.1267.

NextPlat (NXPL)

QualityStocks, InvestorBrandNetwork, MissionIR, SmallCapRelations, SeriousTraders, Stocks to Buy Now, Tiny Gems, BioMedWire, Tip.us, StocksToBuyNow, NetworkNewsWire, TechMediaWire, SmallCapSociety, Web3MediaWire, TinyGems, 360 Wall Street, ChineseWire, MarketClub Analysis, 247 Market News, The Stock Dork and Premium Stock Alerts reported earlier on NextPlat (NXPL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the company’s future following the recent passing of CEO and Chairman Charles M. Fernandez. The letter highlights internal reviews, meetings with subsidiary leaders, and plans for increased focus, coordination, and strategic investment to build on the company’s existing foundation and drive long-term value creation.

To view the full press release, visit: https://ibn.fm/jGgfX

About NextPlat Corp

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.

NextPlat (NXPL), closed Monday's trading session at $0.7429, off by 0.1478495%, on 31,718 volume. The average volume for the last 3 months is 1,179,957 and the stock's 52-week low/high is $0.43/$2.3.

HealthLynked (HLYK)

QualityStocks, BioMedWire, Tip.us, SmallCapRelations, StocksToBuyNow, TechMediaWire, SmallCapSociety, SeriousTraders, NetworkNewsWire, MissionIR, InvestorBrandNetwork, PCG Advisory, Trades Of The Day, Schaeffer's and PoliticsAndMyPortfolio reported earlier on HealthLynked (HLYK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HealthLynked (OTCQB: HLYK) , a connected healthcare technology company, has named Andrew Mavliev as its new Chief Technology and Product Officer. Mavliev, a seasoned executive with over 15 years of experience in technology strategy and product development, previously served as founding CTO of Aram Meem LLC’s ToYou superapp. At HealthLynked, he will lead efforts to expand its AI-powered healthcare platform, telehealth services, and integrated medical record systems. CEO Dr. Michael Dent praised Mavliev’s track record of scaling secure, compliant DTC platforms, saying his leadership will support the company’s push for more accessible and personalized care.

To view the full press release, visit https://nnw.fm/mQ1KB

About HealthLynked Corp.

HealthLynked Corp. is committed to improving global healthcare by facilitating the efficient exchange of medical information between patients and providers. The company’s network empowers members to actively manage their healthcare through a centralized and secure platform. For more information about HealthLynked Corp., please visit www.healthlynked.com .

HealthLynked (HLYK), closed Monday's trading session at $0.02, up 9.589%, on 46,050 volume. The average volume for the last 3 months is 309,999 and the stock's 52-week low/high is $0.0031/$0.089.

The QualityStocks Company Corner

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Oxylabs CEO Julius Černiauskas believes that although cloud quantum computing (QC) presents significant opportunities for industry, the technology still has notable risks. In a recently published guest blog, Černiauskas said that quantum computing offers "groundbreaking possibilities" and noted that large tech firms such as Amazon, Microsoft, IBM, and Google are making heavy investments in the technology. Specialized tech startups like PsiQuantum and Quantinuum are also making major inroads into the nascent computing and cloud computing segment and challenging established players. With experts predicting that the quantum computing market will generate more than $1 trillion in value for the global economy over the next decade, projections for the industry's future and its impact on the global economy are quite positive. Even so, Černiauskas asked, can we be entirely sure that the benefits associated with quantum computing outweigh its potential dangers? While the technology has the capacity to revolutionize industries such as artificial intelligence, climate modeling, and drug discovery, it also presents major cybersecurity issues due to quantum computing's potential encryption-breaking abilities. Exponentially more powerful encryption standards will be needed to beef up cybersecurity and protect private networks from quantum computing-aided infiltration. One key approach will be adopting crypto agility, which allows systems to quickly switch to stronger encryption standards as threats evolve, helping defend against harvest now, decrypt later (HNDL) attacks and future-proofing sensitive data. As entities like D-Wave Quantum Inc. (NYSE: QBTS) work to advance quantum computing, more effort needs to be invested by other stakeholders to address the challenges that could come from rendering the current computing systems obsolete or inadequate. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Monday's trading session at $14.64, up 4.4223%, on 2,968,238 volume. The average volume for the last 3 months is 61,949,608 and the stock's 52-week low/high is $0.7505/$19.765.

Recent News

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

ESGold (CSE: ESAU) (OTCQB: ESAUF) announced the expansion of its Montauban Project mine building from 2,000 to 4,000 square feet to support its transition into gold and silver production. The upgraded facility will include crew accommodations, control rooms, a secure lab, and an expanded "Gold Room" for dore storage. As construction accelerates, ESGold also awaits lab results from railbed pre-concentrate samples, an updated Preliminary Economic Assessment, and final Ambient Noise Tomography imaging, all aimed at refining its scalable processing model and district-scale exploration plans.

To view the full press release, visit https://ibn.fm/ncXEG

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

Investment Considerations
  • Fully Permitted & Funded for Near-Term Production: Construction underway soon at Montauban with gold-silver production expected in Q3 2025.
  • Tailings-to-Cashflow Strategy: Near-term cash flow from processing historic tailings will fund exploration across the district-scale land package.
  • Replicable Clean Mining Model: Scalable approach to legacy mine redevelopment in Canada and globally.
  • Broken Hill Analogue: Geological and structural parallels suggest Montauban may host a larger, mineralized system at depth.
  • Modern 3D Imaging Tech: Cutting-edge ANT survey is producing subsurface imaging beyond 800m, uncovering the potential size of the deposit.

ESGold Corp. (OTCQB: ESAUF), closed Monday's trading session at $0.87, up 3.4138%, on 173,545 volume. The average volume for the last 3 months is 286,500 and the stock's 52-week low/high is $0.0221/$0.98.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Despite the critical importance of rare earth element metals, the United States has long been dependent on imports to provide an adequate supply.

Ucore has secured a $18.4 million funding agreement from the U.S. DoD to support the development of its rare earth processing facility in Louisiana.

Ucore CEO notes that the funding validates the company's technological leadership, underscores the strategic value of domestic REE processing.

As global competition intensifies over the control and supply of critical minerals, the United States is taking aggressive steps to secure domestic sources of rare earth elements ("REEs")—materials essential for defense systems, electronics and clean energy. A recent announcement from Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) highlights a significant milestone in this effort. The company has secured a $18.4 million funding agreement from the U.S. Department of Defense ("DoD") to support the development of Ucore's rare earth processing facility in Louisiana. The project represents a major step toward American independence in the global REE supply chain, which is currently dominated by China.

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

 

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Investment Considerations
  • The company is closely aligned with national policy, receiving funding from both the U.S. Department of Defense ($18.4 million) and Natural Resources Canada (C$4.3 million).
  • Ucore’s RapidSX™ platform promises to deliver faster REE separation than traditional SX and is being commercialized at scale.
  • The Louisiana SMC aims to ramp to 7,500 TPA rare earth oxide production and benefits from FTZ status, DoD funding, and private equity backing.
  • Ucore’s 100%-owned Bokan-Dotson Ridge project remains a potentially valuable strategic heavy REE resource supported by a $145M AIDEA bond.
  • As China imposes REE export restrictions and the U.S. escalates domestic production policy, Ucore is positioned as a secure Western alternative.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Monday's trading session at $0.8235, up 0.0121448%, on 80,421 volume. The average volume for the last 3 months is 469,480 and the stock's 52-week low/high is $0.33/$1.64.

Recent News

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF)

The QualityStocks Daily Newsletter would like to spotlight Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF).

Nevada's Walker Lane area is becoming a prime target for mineral exploration

Lahontan Gold is focused on becoming a strategic player in the Walker Lane region

Lahontan's strategic execution, focused on resource growth and economic evaluation, mirrors the broader resurgence of Walker Lane as a target-rich environment

LGCXF recently launched new metallurgical testing at its Santa Fe deposit, aiming at improving gold and silver mineralization

Nevada's Walker Lane region has emerged as one of North America's most compelling gold and silver frontiers — and Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is strategically placed to capitalize on that fact, owning and developing four high-potential exploration properties in the area. With a vision to evolve into Nevada's premier silver and gold producer, Lahontan has built a robust portfolio of distillery-scale assets across this geologically diverse and historically rich trend.

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) is a Canadian mine development and exploration company advancing a portfolio of gold and silver assets in Nevada’s Walker Lane, one of the world’s most productive and mining-friendly regions. Through its U.S. subsidiaries, the company controls four gold and silver properties in Nevada, three of which are 100%-owned and one controlled via a low-cost option to acquire full ownership. With a clear near-term path to production, Lahontan is focused on unlocking oxide gold and silver value from past-producing, infrastructure-rich projects.

The company’s mission is to responsibly develop and expand its oxide resources while minimizing capital intensity and maximizing economic returns. Leveraging a strong technical team with a track record of advancing projects and building mines, Lahontan is focused on growing gold and silver resources and hitting permitting milestones across multiple sites. Its strategy prioritizes scalability, efficiency, and timely value realization for shareholders.

By maintaining full project ownership and a capital-light development model, Lahontan Gold is positioned to rapidly transition from development to production.

The company is headquartered in Toronto, Ontario.

Projects

Santa Fe Mine

The 26.4 km² Santa Fe Mine is Lahontan’s flagship asset and core development priority. A past-producing open-pit, heap-leach gold and silver operation, Santa Fe historically yielded more than 359,000 ounces of gold and 702,000 ounces of silver between 1988 and 1995. The site benefits from established infrastructure—including power, water, and road access—and more than 79% of its known resources are unencumbered by royalties.

A 2024 NI 43-101 resource estimate outlines 1.54 million ounces of gold equivalent (AuEq) in the Indicated category and 0.41 million ounces Inferred, all pit-constrained. Oxide resources average among the highest grades in the state and are distributed across five known deposits. A 2025 Preliminary Economic Assessment (PEA) projects strong economic returns, including an after-tax NPV5% of $200 million, a 34.2% internal rate of return (IRR), and average annual production of approximately 50,000 ounces AuEq over an eight-year mine life.

Permitting is well underway for both the Exploration and Mine Plans of Operation, covering over 12 km² and more than 700 drill holes. The company is targeting construction permits in late 2026 and continues to pursue oxide resource expansion and metallurgical optimization, particularly within the Slab-Calvada corridor.

West Santa Fe

West Santa Fe lies just 13 kilometers from the flagship and is being explored as a potential satellite operation. The project is defined by a shallow, oxide-dominant gold-silver system with a conceptual target of 0.5 to 1.0 million ounces AuEq based on historic drilling and recent surface sampling, which returned up to 2.61 g/t Au and 899 g/t Ag (14.6 g/t AuEq). A 6,300-meter Phase One reverse circulation drill program is scheduled for 2025 to validate historical data and support a maiden resource estimate. Development is streamlined under a low-cost option agreement and a rapid permitting path via Notice of Intent.

Moho and Redlich

The Moho and Redlich projects provide additional longer-term upside within Lahontan’s portfolio. Moho features high-grade, oxidized epithermal veins with historic production at grades of 20–25 g/t Au and 300 g/t Ag. A 2019 core drill program confirmed the presence of high-grade mineralization at depth. Redlich, located along trend from the historic Candelaria silver mine, hosts disseminated Ag mineralization in epithermal veins and hydrothermal breccias but remains untested by drilling. While no near-term programs are currently disclosed, both assets represent future exploration optionality.

Market Opportunity

Lahontan Gold operates in Nevada, consistently ranked the top global mining jurisdiction by the Fraser Institute due to its transparent permitting process, legal stability, and established infrastructure. Nevada produces over 4.5 million ounces of gold annually, generating approximately $9 billion in value, and ranks fifth globally in total gold production.

According to the World Gold Council, total gold demand in Q1 2025 reached 1,206 tonnes, up 1% year-over-year, marking the strongest first quarter since 2016. Central banks added 244 tonnes to reserves, a slight slowdown from the prior quarter but well within the strong buying range observed over the past three years. Meanwhile, silver demand is supported by strong industrial usage in solar panels, electric vehicles, and semiconductors, with long-term deficits forecast in the physical silver market.

With macro-driven demand for gold, technology-driven silver consumption, and strong institutional buying across both metals, Lahontan is uniquely positioned to capitalize through its portfolio of oxide-focused projects in a top-tier jurisdiction—offering near-term production potential and longer-term resource expansion.

Leadership Team

Kimberly Ann, Founder, CEO, President & Executive Chair, is a veteran mining executive with a track record of founding and scaling junior resource companies. She has raised over $210M in financing and led the $340M buyout of Prodigy Gold. Her prior roles include CFO of PPX Mining and founder of Latin America Resource Group, which merged with Carube Copper to form C3 Metals.

Brian Maher, Founder and VP of Exploration, is an economic geologist with more than 45 years of experience. He previously led Prodigy Gold as CEO, where he helped develop the Magino gold project before its $341M acquisition. His career includes senior roles at ASARCO, Hochschild Mining, and PPX Mining, where he oversaw exploration and production in the Americas.

John McNeice, Chief Financial Officer, is a Chartered Professional Accountant with three decades of experience in public company reporting. He has served as CFO for seven public resource companies and played a key role in Ur-Energy Inc.’s TSX IPO and $150M in financings. He also serves as CFO for Gold79 Mines, C3 Metals, and Northern Graphite Corp.

Current Initiatives
  • Commencing Summer gold and silver resource expansion drilling at Santa Fe
  • Optimizing Preliminary Economic Assessment reflecting +$3,000 gold price
  • Exploration Plan of Operations heading into NEPA stage with approval expected Q4 2025
  • Targeting late 2026 mining permit and breaking ground at Santa Fe in 2027
Investment Considerations
  • The Santa Fe Mine hosts 1.95 million ounces of pit-constrained gold equivalent resources across Indicated and Inferred categories.
  • A 2025 Preliminary Economic Assessment for Santa Fe outlines an after-tax NPV5% of $200 million and a 34.2% IRR based on spot pricing.
  • All four projects are 100%-owned or under low-cost acquisition agreements, with development centered in Nevada, the world’s top mining jurisdiction.
  • Near-term catalysts include Santa Fe permitting milestones, West Santa Fe’s maiden drill program, and an updated economic study.
  • The company is led by a proven team with multiple M&A exits and extensive experience in advancing heap-leach gold operations.

Lahontan Gold Corp. (OTCQB: LGCXF), closed Monday's trading session at $0.076, up 4.5392%, on 356,924 volume. The average volume for the last 3 months is 535,290 and the stock's 52-week low/high is $0.0143/$0.0904.

Recent News

ONAR Holding Corp. (OTCQB: ONAR)

The QualityStocks Daily Newsletter would like to spotlight ONAR Holding Corp. (OTCQB: ONAR).

ONAR (OTCQB: ONAR) issued a shareholder letter highlighting 79% year-over-year revenue growth in Q1 2025 to $1.07 million, driven by its strategic acquisition and integration of Integrum Group, now rebranded as ONAR LLC. The company emphasized its sharpened focus on high-margin, technology-enabled marketing services through Storia and Of Kos, with 90% of advertising and marketing revenue recurring. ONAR aims to achieve platform-scale profitability by executing pending acquisitions and absorbing fixed public company costs. The letter also outlined ongoing capital structure optimization and reaffirmed the company's commitment to long-term value creation in the evolving digital marketing landscape.

To read the full interview, visit: https://ibn.fm/6y9Yr

ONAR Holding Corp. (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide.

Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. With employees across five continents, the company is aggressively expanding its team to support both organic growth and an active acquisition pipeline. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings across industries.

ONAR’s mission is to drive measurable client success through integrated, high-impact marketing solutions that blend creativity, data science, and technology. As it continues to expand, ONAR is focused on building a global marketing services network that serves companies ranging from $10 million to $300 million in revenue.

The company is headquartered in Miami, Florida.

Portfolio

ONAR’s operations are organized across a network of specialized agencies that together serve more than 45 clients across a wide range of industries. Each agency brings deep domain expertise and a results-driven approach:

  • Storia: A premier performance marketing agency specializing in brand growth, paid media, and SEO. With a focus on data-driven excellence, Storia delivers highly targeted marketing strategies that maximize ROI across digital platforms. The agency partners with leading brands to drive measurable revenue outcomes and long-term brand equity.
  • Of Kos: A full-service healthcare marketing agency committed to redefining the patient experience. Of Kos partners with healthcare professionals to deliver integrated campaigns that not only increase patient engagement but also elevate the standard of care across the healthcare landscape. Its work bridges marketing innovation and healthcare expertise to create real impact.
  • CHALK: An experiential marketing agency that transforms bold ideas into unforgettable, immersive experiences. CHALK’s team of event architects specializes in designing events that break boundaries — from brand activations and pop-ups to major corporate experiences — creating lasting emotional connections between brands and audiences.
  • ONAR Labs: The company’s pioneering technology incubator, ONAR Labs, brings together data scientists, engineers, and industry experts to develop proprietary marketing technologies. Every product is rigorously battle-tested within the agency network before commercialization, ensuring that ONAR Labs delivers real-world solutions that enhance marketing performance and client success.

Market Opportunity

ONAR operates at the intersection of marketing services and marketing technology, two sectors undergoing rapid evolution and expansion. The global digital marketing software market alone is projected to reach $264.15 billion by 2030, expanding at a CAGR of 19.4%, according to Grand View Research. Meanwhile, healthcare marketing and experiential marketing are experiencing renewed momentum, as companies seek to create more personalized and immersive customer experiences.

With its integrated, AI-driven platform and expertise across multiple high-growth verticals, ONAR is well positioned to capture a growing share of the marketing spend from mid-sized to large enterprise clients. As businesses increasingly prioritize digital transformation, customer experience, and data-driven marketing, ONAR’s diversified offerings and proprietary technologies through ONAR Labs create meaningful competitive advantages in a highly fragmented market.

Leadership Team

Claude Zdanow, Chief Executive Officer, is a seasoned entrepreneur and business leader with deep experience scaling service organizations and technology platforms. Prior to founding ONAR, he built and successfully exited multiple companies in marketing and media, combining creative vision with operational discipline to drive measurable client growth.

Chris Becker, President, brings extensive operational and strategic expertise to ONAR, focusing on driving agency performance and expanding the company’s integrated service offering. His leadership emphasizes operational rigor, client success, and scaling the company’s footprint across industries and regions.

Patricia Kaelin, Chief Financial Officer, oversees ONAR’s financial operations and strategic planning. A distinguished financial executive with more than 25 years of experience in scaling high-growth companies and leading finance teams at both public and private companies, she expertly manages financial strategy, M&A transactions, and provides a strong foundation for ONAR’s continued expansion and acquisition initiatives.

Sam Mendez, Chief of Staff, fosters seamless collaboration across the organization. She expertly manages strategic projects, facilitates clear communication channels, and acts as a key point of contact to maximize the executive team’s impact and advance organizational goals.

Investment Considerations
  • ONAR is scaling a diversified, AI-driven marketing network addressing multiple high-growth industry verticals.
  • The company is actively pursuing an acquisition-driven expansion strategy to grow its marketing agency network.
  • ONAR Labs provides a proprietary technology pipeline, offering additional revenue streams beyond traditional marketing services.
  • A strong leadership team with proven track records in business growth, financial management, and technology commercialization positions the company for long-term success.
  • ONAR’s focus on middle market and growth-stage clients aligns with sectors expected to see a sustained rise in marketing spend over the next decade.

ONAR Holding Corp. (OTCQB: ONAR), closed Monday's trading session at $0.0525, up 3.9604%, on 11,000 volume. The average volume for the last 3 months is 2,150 and the stock's 52-week low/high is $0.03/$0.167.

Recent News

Lantern Pharma Inc. (NASDAQ: LTRN)

The QualityStocks Daily Newsletter would like to spotlight Lantern Pharma Inc. (NASDAQ: LTRN).

Lantern Pharma (NASDAQ: LTRN) , a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. "Lantern Pharma's AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline," reads a recent article. "The company has three lead drug candidates in clinical development, targeting major oncology markets including non-small cell lung cancer (‘NSCLC'), triple-negative breast cancer (‘TNBC'), and non-Hodgkin's lymphoma (‘NHL')… Starlight Therapeutics extends Lantern's footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations… Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways."

To view the full article, visit https://ibn.fm/s1B45

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR® platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic™) for non-small cell lung cancer (NSCLC) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (TNBC), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (NHL) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

  • LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
  • LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
  • LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
  • CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

Investment Considerations
  • Lantern Pharma’s AI-driven RADR® platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline.
  • The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL.
  • Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations.
  • Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways.
  • With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support pipeline advancement and platform development.

Lantern Pharma Inc. (NASDAQ: LTRN), closed Monday's trading session at $3.16, off by 0.9404389%, on 150 volume. The average volume for the last 3 months is 55,400 and the stock's 52-week low/high is $2.55/$6.118.

Recent News

SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

A new research project is helping shape the future of clean energy at sea. The North Sea Two (NS2) project recently shared results from large-scale testing of floating offshore solar panels. These tests were done by four key partners, Oceans of Energy, Deltares, TNO, and DNV, inside the Deltares Delta Flume, a special facility built to simulate strong ocean waves like those in the North Sea. The main goal of this project is to create official safety and performance standards for offshore solar systems. Right now, there are no clear rules for how to test or approve these floating systems. This lack of certification makes it harder to grow the offshore solar industry. The NS2 project aims to change that by providing real data that engineers and experts can use to develop safe and trusted offshore solar systems. This four-year project, funded by the Dutch Ministry of Economic Affairs, is an important step toward building large and reliable offshore solar farms. It also shows how offshore solar can work together with offshore wind to create more clean energy for the future. As solar energy generation is re-imagined to incorporate offshore locations, the market for stationary energy storage systems is bound to explode. Companies like SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) focused on the renewable energy ecosystem could see their footprint grow around the globe. 

SolarBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. SolarBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, SolarBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, SolarBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

SolarBank has offices in Toronto, Ontario and New York.

Projects

SolarBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, SolarBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of SolarBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, SolarBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

SolarBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

SolarBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance SolarBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, SolarBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of SolarBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of SolarBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive SolarBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by SolarBank, enhancing its asset portfolio and growth prospects.


Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

SolarBank Corp. (NASDAQ: SUUN), closed Monday's trading session at $1.52, off by 4.4025%, on 192 volume. The average volume for the last 3 months is 554,362 and the stock's 52-week low/high is $1.23/$6.43.

Recent News

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix (NASDAQ: SNGX) is at the forefront of the effort as the medical community urgently seeks alternative treatments for bacterial infections in the face of escalating antibiotic resistance. The company's SGX943 therapy "is based on dusquetide, an Innate Defense Regulator (‘IDR') that modulates the body's immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections," reads a recent article. "The company's portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs."

To view the full article, visit https://ibn.fm/PZfm9

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Investment Considerations
  • Soligenix has multiple late-stage assets with orphan and fast-track designations, providing a clear regulatory pathway toward potential approvals.
  • The company’s pipeline has a total addressable market exceeding $2 billion, spanning rare diseases, inflammation, and biothreat applications.
  • Soligenix has benefited from significant non-dilutive government funding, which reduces operational expenses and financial risk while supporting its public health initiatives.
  • The company is well-positioned for multiple development and regulatory catalysts, and commercial milestones, with lead candidates in cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease.
  • Soligenix is led by an experienced management team with a strong track record of success.

Soligenix Inc. (NASDAQ: SNGX), closed Monday's trading session at $1.31, off by 3.6765%, on 31,669,715 volume. The average volume for the last 3 months is 123,022 and the stock's 52-week low/high is $1.26/$14.8299.

Recent News

Vivakor Inc. (NASDAQ: VIVK)

The QualityStocks Daily Newsletter would like to spotlight Vivakor Inc. (NASDAQ: VIVK).

As governments, consumers, and investors demand cleaner practices and corporate accountability, companies are being urged to innovate and adapt—or risk falling behind. Vivakor (NASDAQ: VIVK) , a vertically integrated energy infrastructure and environmental services company, is positioned for this challenge. Engaged in the transportation, storage, reuse, and remediation of oilfield fluids and waste, Vivakor is proving that environmental responsibility and profitability are not mutually exclusive. Looking ahead, "Vivakor is focused on expanding its environmental services segment, investing in infrastructure that enhances waste oil processing, and advancing technologies that reduce emissions and environmental impact. By positioning itself at the intersection of energy production and environmental innovation, the company is poised to play a vital role in the sustainable-energy landscape of the future."

To view the full article, visit https://ibn.fm/rLMhD

Vivakor Inc. (NASDAQ: VIVK) is a vertically integrated energy infrastructure and environmental services company, focused on the transportation, storage, reuse, and remediation of oilfield fluids and waste. The company operates a large-scale oilfield trucking fleet serving key U.S. energy regions, enabling end-to-end solutions for the handling of crude oil and produced water. Through long-term contracts and strategic asset positioning, Vivakor delivers critical services to upstream energy operators seeking efficient and environmentally responsible operations.

Vivakor’s vision is to become a leader in sustainable energy logistics and remediation by combining innovative infrastructure with environmentally conscious practices. The company’s integrated model allows it to optimize the flow and treatment of petroleum-based materials across the value chain. By owning and operating both the logistics and remediation components, Vivakor is well-positioned to support an evolving energy ecosystem.

The company’s mission is to develop, acquire, accumulate, and operate assets, properties, and technologies that enhance efficiency and sustainability within the energy sector. This includes the ongoing development of oilfield waste remediation facilities, which will facilitate the recovery and reuse of petroleum byproducts.

The company is headquartered in Dallas, Texas.

Operations

Vivakor’s operations span crude oil and produced water gathering, transportation, storage, and remediation. Leveraging a large-scale oilfield trucking fleet, the company delivers mission-critical logistics services under long-term agreements with energy producers. Its integrated facility assets support efficient fluid movement and storage while aligning with evolving environmental standards.

The company is actively developing oilfield waste remediation capabilities designed to recycle and safely dispose of petroleum byproducts. These facilities will process contaminated materials and convert them into reusable resources, supporting more sustainable field operations. In 2023, Vivakor expanded its infrastructure through the acquisitions of Silver Fuels Delhi and White Claw Colorado, strengthening its midstream footprint and operational reach across key U.S. basins.

Vivakor delivered triple-digit revenue growth in 2023, reflecting increased demand for its integrated services and the impact of strategic asset expansion. This momentum positions the company for further scale as environmental regulations and logistics needs continue to evolve across the energy sector.

Market Opportunity

Vivakor operates at the intersection of energy logistics and environmental remediation—two sectors undergoing transformation amid rising regulatory pressure and sustainability goals. According to Allied Market Research, the global oilfield services market was valued at $268.1 billion in 2022 and is projected to reach $346.45 billion by 2032, growing at a CAGR of 2.6% during the forecast period. As producers seek efficiency and environmental compliance, demand for integrated logistics and remediation services is expected to grow.

Additionally, the global produced water treatment market is forecast to reach $12.2 billion by 2028, up from $8.6 billion in 2023, driven by increased recycling efforts and stricter disposal regulations. Vivakor’s remediation facilities, once operational, will directly serve this need by offering oilfield clients sustainable waste processing and reuse options.

By addressing both logistical and environmental challenges in energy production, Vivakor is strategically positioned to capture value across multiple growth verticals in a dynamic market landscape.

Leadership Team

James Ballengee, President & Chief Executive Officer, is an energy entrepreneur and operator with over 15 years of experience in oilfield logistics, midstream infrastructure, and energy asset development. Prior to leading Vivakor, he served as Managing Partner at Silver Fuels Delhi and White Claw Colorado, both of which were acquired by Vivakor in 2023. He has held executive roles in multiple energy companies where he focused on developing vertically integrated logistics and remediation systems. Ballengee specializes in contract structuring, capital deployment, and building operationally efficient service platforms across the energy sector.

Tyler Nelson, Chief Financial Officer, is a licensed CPA with extensive experience in public company financial leadership, SEC reporting, and audit readiness. Prior to joining Vivakor, he served as Corporate Controller at two Nasdaq-listed companies and held audit roles at prominent regional accounting firms. His background spans oil & gas, renewables, and technology, where he has led successful finance transformations, SOX compliance rollouts, and investor reporting improvements. At Vivakor, Nelson oversees all financial operations, capital strategy, and compliance functions.

Investment Considerations
  • Vivakor achieved substantial revenue growth in 2023, driven by expanded logistics operations and newly integrated midstream assets.
  • The company operates a large-scale oilfield trucking fleet under long-term contracts, providing recurring revenue and service continuity.
  • Its remediation facilities, once operational, will address a produced water treatment market forecast to reach $12.2 billion by 2028.
  • Recent acquisitions have enhanced Vivakor’s infrastructure footprint and extended its service reach across key U.S. energy basins.
  • The company’s integrated model aligns with industry trends favoring sustainability, compliance, and full-cycle fluid management.

Vivakor Inc. (NASDAQ: VIVK), closed Monday's trading session at $0.8, off by 1.4778%, on 890 volume. The average volume for the last 3 months is 1,593,094 and the stock's 52-week low/high is $0.5504/$3.45.

Recent News

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

NGTF combines AI-powered robotics technology with strategic hotel acquisitions, expanding into new vision for next-generation hospitality solutions

Recent executive appointments have brought decades of hotel operations expertise and supply chain innovation to accelerate the company's deployment

Major hotel advancements, including a LOI to acquire a $36.93 million Hilton Garden Inn deal adjacent to Disney's Cotino development, to position NGTF as a flagship automation showcase

The hospitality industry stands at a technological crossroads. With shortages continuing to challenge hotel operations and guests demanding enhanced service experiences, the sector faces unprecedented pressure to innovate. Traditional staffing models are proving inadequate, with many properties struggling to maintain service standards while controlling costs. This disruption has created a massive opportunity for niche curiosities to evolve into proven hospitality assets. Enter Nightfood Holdings (OTCQB: NGTF), a company uniquely positioned to scale up this transformation through its integrated approach of AI-powered robotics deployment and strategic hotel ownership.

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

  • Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
  • Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

  • Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
  • Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
  • Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

  • Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
  • Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
  • Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Investment Considerations
  • Dual Growth Strategy – NGTF combines hotel acquisitions with AI-powered automation, creating an integrated model that maximizes operational efficiency and revenue potential.
  • Expanding Robotics-as-a-Service (RaaS) – Subscription-based robotic automation solutions designed to reduce operational costs and address labor shortages for hotel operators.
  • Strategic Hotel Acquisitions – Acquiring a variety of hospitality assets, from midscale to luxury, to serve as testing grounds for AI-driven automation and to drive profitability.
  • Proven Market Demand – Rising labor costs and increasing adoption of service robotics are fueling demand for automation in hospitality, positioning NGTF as an early leader in the sector.
  • Scalable & Revenue-Generating Model – By owning hotels and offering RaaS to third-party operators, NGTF is building a diversified, high-growth business model.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Monday's trading session at $0.018, off by 10%, on 434,524 volume. The average volume for the last 3 months is 348,660 and the stock's 52-week low/high is $0.0053/$0.0571.

Recent News

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM)

The QualityStocks Daily Newsletter would like to spotlight Silvercorp Metals Inc. (TSX.V: SVM) (NYSE American: SVM).

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) is a Canadian mining company producing silver, gold, lead, and zinc, with a long history of profitability and growth. The company focuses on creating shareholder value by generating free cash flow from long-life mines, expanding through organic growth opportunities in China and Ecuador, and pursuing strategic mergers and acquisitions. Silvercorp has built a reputation as a low-cost producer with a commitment to responsible mining practices.

With over 18 years of operating experience, Silvercorp has developed a diversified portfolio of mining assets and investments in China, Ecuador, and Bolivia. The company leverages its expertise in exploration and operational efficiency to enhance the value of its projects while maintaining a strong balance sheet. Silvercorp’s disciplined approach to mine expansion and resource development ensures long-term sustainable growth.

The company’s mission is to build and operate profitable mines that generate sustainable economic, social, and environmental benefits for stakeholders. Silvercorp is committed to responsible mining, with a focus on environmental stewardship and community engagement.

The company is headquartered in Vancouver, Canada.

Portfolio

Silvercorp operates a diverse portfolio of producing mines, construction-stage projects, and exploration assets across multiple jurisdictions. The company focuses on optimizing production from existing operations while strategically advancing new projects to drive future growth.

  • Ying Mining District (China) – The company’s flagship operation consists of several underground mines producing silver, gold, lead and zinc in concentrates. In fiscal 2025, Ying produced 6.9 million ounces of silver and 7,495 ounces of gold, along with lead and zinc by-products. Fiscal 2026 guidance calls for continued production growth as ongoing mine optimization efforts continue to bear fruit.
  • GC Mine (China) – A silver-lead-zinc mine with a history of consistent production and ongoing resource expansion through drilling. While production dipped slightly in fiscal 2025, output is expected to increase in fiscal 2026.
  • El Domo (Ecuador) – A fully-permitted, copper-gold project under construction. In April 2025, Silvercorp announced a detailed and fully-funded $240.5 million construction plan. Major contracts have been awarded and construction activities are underway, with commissioning expected by December 2026.
  • Condor Project (Ecuador) – A gold exploration asset with significant resources. In May 2025, Silvercorp published an updated mineral resource estimate focusing on high-grade underground zones. A revised PEA is expected by the end of 2025, alongside continued permitting and community engagement efforts.
  • Kuanping Project (China) – A permitted gold-lead-zinc satellite project north of Ying. Mine construction is underway and Kuanping will be an underground mine with ore to be milled at the Ying complex.
  • BYP Mine (China) – A gold-lead-zinc project that operated previously and is now undergoing permitting as a gold mine.
  • Bolivian Assets – Silvercorp holds a 28% stake in New Pacific Metals (TSX: NUAG, NYSE American: NEWP), providing indirect exposure to two world class silver projects: Silver Sand and Carangas.

Through its diversified portfolio, Silvercorp delivers exposure to operations generating growing cash-flow, as well as high-potential growth projects that will create long-term value for shareholders.

Market Opportunity

The global demand for silver, gold, and base metals remains strong, driven by industrial applications, investment demand, and renewable energy initiatives. Silvercorp is well positioned to capitalize on rising silver demand, particularly in China, where 80% of the world’s solar panels are manufactured—an industry heavily reliant on silver.

Ecuador’s mining sector is experiencing rapid growth, with government support for foreign investment and infrastructure improvements. Mining exports in the country surged from $275 million in 2018 to $3.3 billion in 2023, highlighting the sector’s increasing economic importance. Silvercorp’s El Domo and Condor projects are poised to become key contributors to Ecuador’s mining expansion.

Industry forecasts indicate continued growth in silver and base metal prices, benefiting producers with strong operational performance and cost controls. Silvercorp’s diversified asset base and low-cost production profile provide resilience against market fluctuations, positioning the company for long-term value creation.

Leadership Team

Rui Feng, Ph.D., Chairman & CEO, founded Silvercorp and has over 30 years of experience in mineral exploration and mining. He has been instrumental in leading the company’s strategic vision, transforming it into a profitable, low-cost silver producer with a diversified asset base. Under his leadership, Silvercorp has expanded its global footprint, acquiring and developing high-value mining projects across China, Ecuador, and Bolivia. Dr. Feng’s expertise in geology and resource development has contributed to major mineral discoveries, and his disciplined approach to capital allocation has positioned the company for long-term growth.

Derek Liu, MBA, CGA, CPA, Chief Financial Officer, brings over two decades of financial leadership experience in the mining sector, overseeing capital allocation, financial strategy, and risk management. He has played a crucial role in maintaining Silvercorp’s strong balance sheet and financial discipline, ensuring the company remains well-capitalized for organic growth and strategic acquisitions. His expertise in financial planning, compliance, and investor relations has supported Silvercorp’s continued profitability and operational efficiency in a competitive global mining landscape.

Lon Shaver, CFA, President, has extensive experience in corporate finance, equity research, and capital markets, providing strategic guidance on business development and investor relations. Before joining Silvercorp, he held senior roles in investment banking and asset management, where he advised mining companies on financing, mergers, and acquisitions. His deep understanding of capital markets and industry dynamics helps drive Silvercorp’s corporate growth initiatives, enhance shareholder value, and strengthen relationships with institutional investors and stakeholders.

Investment Considerations
  • Fiscal 2025 marked record revenues of nearly $299 million, with silver production of 6.9 million ounces and 11% year-over-year growth in silver equivalent output.
  • The company maintains industry-leading margins with an all-in sustaining cost of $12.12 per ounce of silver over the last 12 months, reinforcing its position as a low-cost producer.
  • The company maintains a strong balance sheet with over $369 million in cash and a strategic equity portfolio, ensuring financial flexibility for future growth.
  • The company launched construction of its fully funded El Domo copper-gold mine in 2025, with production expected by the end of 2026.
  • Silvercorp has published an updated mineral resource estimate for the Condor Project and expects to issue a revised PEA by year-end 2025.
  • Silvercorp is committed to strong environmental and social governance practices, holding an MSCI ESG rating of “A” and prioritizing local employment and procurement.

Silvercorp Metals Inc. (NYSE American: SVM), closed Monday's trading session at $4.22, up 3.6855%, on 34,877 volume. The average volume for the last 3 months is 7,359,149 and the stock's 52-week low/high is $2.87/$5.32.

Recent News

Intelligent Bio Solutions Inc. (NASDAQ: INBS)

The QualityStocks Daily Newsletter would like to spotlight Intelligent Bio Solutions Inc. (NASDAQ: INBS).

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings such as opiates, cocaine, methamphetamine, and cannabis. This innovative approach positions INBS to transform drug testing protocols, particularly in industries where safety and speed are mission critical.

The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system empowers companies and organizations to screen more efficiently. INBS continues to drive adoption in international markets, with customers spanning construction, logistics, healthcare, government, and drug treatment sectors.

INBS’s mission is centered on delivering accessible, transformative solutions that improve lives and operational safety. As the company expands toward a planned U.S. market launch in 2025, it is also strengthening its intellectual property portfolio and localizing solutions for Spanish-speaking regions.

The company is headquartered in New York, New York.

Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions’ flagship offering is the Intelligent Fingerprinting Drug Screening System, a portable, three-part solution that includes a fingerprint collection cartridge, a lateral flow-based DSR-Plus reader, and software for rapid drug screening. Designed to be used on-site, this system eliminates the complexities and hazards of urine and saliva tests, offering a clean, fast, and non-invasive alternative.

The system screens for a broad range of substances including opiates, methamphetamine, cocaine, cannabis, benzodiazepines, and more. Its cost advantage is significant — point-of-care fingerprint tests cost approximately $20, compared to $300 for typical urine or saliva testing. The platform includes over 1,000 DSR-Plus Readers installed across customer sites, supporting a base of more than 450 active customer accounts globally. In clinical studies, the system demonstrated 94.1% accuracy and 100% specificity, providing a credible foundation for future FDA approvals and market expansion.

In addition to drug screening, INBS is developing a proprietary biosensor platform designed to detect specific biomarkers from non-invasive samples such as sweat, saliva, and interstitial fluid. These additional applications remain under development.

Market Opportunity

Intelligent Bio Solutions operates at the intersection of workplace safety, public health, and diagnostic innovation. The company is targeting the drug screening products market, which is projected to reach $14.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.1%, according to Research and Markets.

In the U.S., substance abuse is a $400 billion issue, with more than 70% of individuals using illicit drugs or alcohol currently employed. This presents an urgent need for scalable, workplace-compatible screening technologies. Industries such as transportation, construction, mining, and healthcare are among the highest adopters of employee drug testing protocols, driven by regulatory requirements and safety imperatives.

INBS’s non-invasive solution is well-positioned to capitalize on trends toward less invasive, faster, and more convenient testing methods — potentially displacing legacy systems reliant on urine or saliva testing, which have longer turnaround times and greater administrative burdens.

Leadership Team

Harry Simeonidis, Chief Executive Officer, has over 25 years of experience across the healthcare, pharmaceutical, and life sciences industries. He previously served as General Manager for Surgery, Asia Pacific at GE Healthcare. Prior to that, he was President and CEO of GE Healthcare ANZ, where he led significant market share growth.

Spiro Sakiris, Chief Financial Officer, brings 34 years of expertise in accounting, taxation, IPO preparation, and capital raising. He is highly experienced with IFRS and U.S. GAAP applications in the life sciences sector and is a member of the Institute of Chartered Accountants of Australia & New Zealand.

Investment Considerations
  • INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030.
  • The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts.
  • Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods.
  • The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway.
  • INBS is led by a seasoned executive team with global healthcare and commercialization experience.

Intelligent Bio Solutions Inc. (NASDAQ: INBS), closed Monday's trading session at $1.72, up 12.4183%, on 9,173 volume. The average volume for the last 3 months is 144,459 and the stock's 52-week low/high is $1/$3.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.